PPD, Inc. (PPD) |
| 47.28 0 (0%) 04-24 15:47 |
| Open: | 47.32 |
| High: | 47.4 |
| Low: | 47.24 |
| Volume: | 1,868,187 |
| Market Cap: | 0(M) |
| PE Ratio: | 0 |
| Exchange: | NASDAQ Global Select |
| Industry: | Drug Manufacturers - Specialty & Generic |
| Sector: | Healthcare |
| Technical analysis | ||||
![]() |
||||
| sell | buy | |||
| Resistance 2: | 153.29 |
| Resistance 1: | 131.24 |
| Pivot price: | 124.00 |
| Support 1: | 121.06 |
| Support 2: | 114.77 |
| 52w High: | 47.41 |
| 52w Low: | 31.54 |
PPD, Inc. provides drug development services to the biopharmaceutical industry worldwide. The company operates through Clinical Development Services and Laboratory Services segments. It offers clinical development services, including product development and consulting, early development, Phases II-IV clinical trial management, accelerated enrollment, peri- and post-approval, and medical communications services. The company also provides laboratory services comprising bioanalytical, biomarker, vaccine science, good manufacturing practice, and central laboratory services. It serves pharmaceutical, biotechnology, medical device, and government organizations, as well as other industry participants. The company was founded in 1985 and is headquartered in Wilmington, North Carolina.
| EPS | 0.000 |
| Book Value | 0.000 |
| PEG Ratio | 0.00 |
| Gross Profit | 0.000 |
| Profit Margin (%) | 0.00 |
| Operating Margin (%) | 0.00 |
| Return on Assets (ttm) | 0.0 |
| Return on Equity (ttm) | 0.0 |
Mon, 06 Apr 2026
Lipocine adds to PPD setbacks as Tepezza scores, batoclimab misses in TED - BioCentury
Thu, 02 Apr 2026
Textron Systems Awarded $450m Advanced Reconnaissance Vehicle (ARV) Pre-Production Development (PPD) Award By U.S. Marine Corps - Textron Inc. - Investor Relations
Thu, 02 Apr 2026
Phase 3 PPD trial for Lipocine (NASDAQ: LPCN) drug falls short - Stock Titan
Wed, 18 Feb 2026
Lipocine Announces Last Patient Last Visit in Pivotal Phase 3 Trial of LPCN 1154 for Postpartum Depression (PPD) - PR Newswire
Tue, 16 Dec 2025
Lipocine's PPD Phase 3 Study (LPCN 1154) Hits 80% Enrollment Milestone - PR Newswire
Mon, 18 Aug 2025
Reunion Neuroscience Announces Positive Topline Results from RECONNECT Phase 2 Clinical Trial of RE104 for the Treatment of Postpartum Depression (PPD) - GlobeNewswire
|
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |